Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Detalles Bibliográficos
Autores principales: Petereit, Hela-Felicitas, Tumani, Hayrettin, Zettl, Uwe K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182197/
https://www.ncbi.nlm.nih.gov/pubmed/34158837
http://dx.doi.org/10.1177/17562864211022581
_version_ 1783704157002137600
author Petereit, Hela-Felicitas
Tumani, Hayrettin
Zettl, Uwe K.
author_facet Petereit, Hela-Felicitas
Tumani, Hayrettin
Zettl, Uwe K.
author_sort Petereit, Hela-Felicitas
collection PubMed
description
format Online
Article
Text
id pubmed-8182197
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-81821972021-06-21 Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies Petereit, Hela-Felicitas Tumani, Hayrettin Zettl, Uwe K. Ther Adv Neurol Disord Letter to the Editor SAGE Publications 2021-06-03 /pmc/articles/PMC8182197/ /pubmed/34158837 http://dx.doi.org/10.1177/17562864211022581 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Letter to the Editor
Petereit, Hela-Felicitas
Tumani, Hayrettin
Zettl, Uwe K.
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
title Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
title_full Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
title_fullStr Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
title_full_unstemmed Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
title_short Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
title_sort correspondence: humoral immune response to covid-19 mrna vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182197/
https://www.ncbi.nlm.nih.gov/pubmed/34158837
http://dx.doi.org/10.1177/17562864211022581
work_keys_str_mv AT petereithelafelicitas correspondencehumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
AT tumanihayrettin correspondencehumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
AT zettluwek correspondencehumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies

Ejemplares similares